人乳腺癌细胞EFM-192A
BLUEFBIO™ Product Sheet
细胞名称 |
人乳腺癌细胞EFM-192A |
||
货物编码 |
BFN60808557 |
||
产品规格 |
T25培养瓶x1 |
1.5ml冻存管x2 |
|
细胞数量 |
1x10^6 |
1x10^6 |
|
保存温度 |
37℃ |
-198℃ |
|
运输方式 |
常温保温运输 |
干冰运输 |
|
安全等级 |
1 |
||
用途限制 |
仅供科研 2类 |
培养体系 |
DMEM高糖+10%FBS+1%三抗 |
||
培养温度 |
37℃ |
二氧化碳浓度 |
5% |
简介 |
人乳腺癌细胞EFM-192A取自46岁女性。该细胞源于DSMZ |
||
注释 |
Part of: Cancer Cell Line Encyclopedia (CCLE) project. Part of: COSMIC cell lines project. Part of: GrayJW Breast Cancer Cell Line Panel. Part of: MD Anderson Cell Lines Project. Doubling time: ~9 days (DSMZ); 80.21 hours (https://www.synapse.org/#!Synapse:syn2347014). Microsatellite instability: Stable (MSS) (Sanger). Omics: CNV analysis. Omics: Deep exome analysis. Omics: Deep quantitative proteome analysis. Omics: Deep RNAseq analysis. Omics: DNA methylation analysis. Omics: Protein expression by reverse-phase protein arrays. Omics: SNP array analysis. Omics: Transcriptome analysis. |
||
基因突变 |
Heterozygous for PIK3CA p.Cys420Arg (c.1258T>C) (CCLE; Cosmic-CLP). Heterozygous for TP53 p.Glu271fs*1 (c.807_808insT) (CCLE; Cosmic-CLP). |
||
HLA信息 |
Class I HLA-A A*01:01,24:02 HLA-B B*07:02,39:01 HLA-C C*12:03,07:02 Class II HLA-DQ DQB1*06:02,02:02 HLA-DR DRB1*15:01,09:10 |
||
STR信息 |
Amelogenin X CSF1PO 12,13 D3S1358 16 D5S818 12,13 D7S820 8,11 D8S1179 9,15 D13S317 9,14 D16S539 8,13 D18S51 17 D21S11 32.2 FGA 20,22 Penta D 9 Penta E 14,16 TH01 7 TPOX 8,10 vWA 16
|
||
参考文献 |
PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005 Li J., Zhao W., Akbani R., Liu W., Ju Z., Ling S., Vellano C.P., Roebuck P., Yu Q., Eterovic A.K., Byers L.A., Davies M.A., Deng W., Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D., Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y., Mills G.B., Liang H. Characterization of human cancer cell lines by reverse-phase protein arrays. Cancer Cell 31:225-239(2017)
PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747 Dutil J., Chen Z., Monteiro A.N., Teer J.K., Eschrich S.A. An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines. Cancer Res. 79:1263-1273(2019)
PubMed=31068700; DOI=10.1038/s41586-019-1186-3 Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C., McDonald E.R. III, Barretina J., Gelfand E.T., Bielski C.M., Li H., Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F., Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R., Lu Y., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C., Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A., Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D., Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L., Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A., Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D., Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M., Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R., Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A., Sellers W.R. Next-generation characterization of the Cancer Cell Line Encyclopedia. Nature 569:503-508(2019)
PubMed=31978347; DOI=10.1016/j.cell.2019.12.023 Nusinow D.P., Szpyt J., Ghandi M., Rose C.M., McDonald E.R. III, Kalocsay M., Jane-Valbuena J., Gelfand E., Schweppe D.K., Jedrychowski M., Golji J., Porter D.A., Rejtar T., Wang Y.K., Kryukov G.V., Stegmeier F., Erickson B.K., Garraway L.A., Sellers W.R., Gygi S.P. Quantitative proteomics of the Cancer Cell Line Encyclopedia. Cell 180:387-402(2020)
|